デフォルト表紙
市場調査レポート
商品コード
1058819

百日咳ワクチンの世界市場(2021年~2028年)

Global Pertussis Vaccine Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.18円
百日咳ワクチンの世界市場(2021年~2028年)
出版日: 2022年02月16日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の百日咳ワクチン市場について調査分析し、市場力学、業界分析、市場分析、競合情勢など、体系的な情報を提供しています。

目次

第1章 世界の百日咳ワクチンの市場方法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 世界の百日咳ワクチン市場-市場の定義と概要

第3章 世界の百日咳ワクチン市場-エグゼクティブサマリー

  • 市場の内訳:製品タイプ別
  • 市場の内訳:ワクチンタイプ別
  • 市場の内訳:エンドユーザー別
  • 市場の内訳:地域別

第4章 世界の百日咳ワクチン市場-市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の百日咳ワクチン市場-業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ

第6章 世界の百日咳ワクチン市場-COVID-19分析

  • 市場でのCOVID-19の分析
    • COVID-19以前の市場シナリオ
    • 現在のCOVID-19の市場シナリオ
    • COVID-19以後の市場シナリオ/将来の市場シナリオ
  • COVID-19における価格の力学
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の百日咳ワクチン市場:製品タイプ別

  • イントロダクション
  • 市場規模分析、および前年比成長分析(%):製品タイプ別
  • 市場魅力指数:製品タイプ別
    • DTaPワクチン*
    • 三種混合ワクチン

第8章 世界の百日咳ワクチン市場:ワクチンタイプ別

  • イントロダクション
  • 市場規模分析、および前年比成長分析(%):ワクチンタイプ別
  • 市場魅力指数:ワクチンタイプ別
    • 全細胞ワクチン
    • 無細胞ワクチン

第9章 世界の百日咳ワクチン市場:エンドユーザー別

  • イントロダクション
    • 市場規模分析、および前年比成長分析(%):エンドユーザー別
    • 市場魅力指数:エンドユーザー別
  • 病院*
    • イントロダクション
    • 市場規模分析(100万米ドル)(2019年~2028年)、および前年比成長分析(%)(2020年~2028年)
  • クリニック
  • 予防接種センター
  • その他

第10章 世界の百日咳ワクチン市場:地域別

  • イントロダクション
    • 市場規模分析(100万米ドル)(2019年~2028年)、および前年比成長分析(%)(2020年~2028年):地域別
    • 市場魅力指数:地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東とアフリカ

第11章 世界の百日咳ワクチン市場-競合情勢

  • 主な発展と戦略
  • 企業シェア分析
  • 製品のベンチマーク

第12章 世界の百日咳ワクチン市場-企業プロファイル概要

  • GlaxoSmithKline*
    • 企業概要
    • 製品ポートフォリオおよび説明
    • 主要ハイライト
    • 財務概要
  • Sanofi
  • Novartis AG
  • Seqirus
  • Merck Sharp & Dohme Corp
  • Astellas Pharma US, Inc.
  • KM Biologics

第13章 世界の百日咳ワクチン市場-DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMPH4683

Market Overview

The global pertussis vaccine market size was valued at US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Whooping cough is treated with a pertussis vaccine. This vaccine is only available in conjunction with other vaccines. All children, babies, teenagers, and pregnant women should get vaccinated against pertussis.

Market Dynamics

Various factors such as growth in the adoption of pertussis vaccination are expected to drive the market growth.

The adoption of pertussis vaccination is expected to drive the market growth

Pertussis vaccines help protect babies, children, and adults from whooping cough, a respiratory disease. Uncontrollable, violent coughing fits characterize whooping cough. It can lead to severe complications in babies. To protect against whooping cough, all infants, children, and adults should receive a vaccine. The vaccine protects people, particularly infants, from contracting pertussis. Infants are especially vulnerable to whooping cough. Babies with whooping cough are at risk of developing pneumonia (lung infection), uncontrollable shaking, and even brain damage. Because whooping cough begins with mild, cold-like symptoms, many people are unaware they have the infection. Without vaccination, people can easily spread whooping cough to others during the early stages of infection. The CDC recommends whooping cough vaccination for all infants and children, preteens and teenagers, and pregnant women. Adults who never received a Tdap dose should also be immunized against pertussis.

The increasing advantage of the pertussis vaccine is expected to boost market growth. For instance, on January 15th, 2019, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap) vaccines, the FDA approved, are used to include repeat vaccination help protect against tetanus, diphtheria, and pertussis. Sanofi manufactures the vaccine under the brand name Adacel. Hence, the growing adoption of pertussis vaccination among people is expected to drive market growth.

The side effects associated with the pertussis vaccine is expected to hamper the market growth

Vaccines, like all medications, may cause side effects. Most side effects are minor, last only a short time, and do not cause long-term problems. The whooping cough vaccine may cause fever, redness, soreness, or swelling where the injection was given, nausea, headache, tiredness, and aching muscles. Serious side effects are extremely uncommon, including severe allergic reactions. These side effects may be more severe in some people. They may temporarily disrupt daily activities. Three out of every hundred people who received Tdap or Td experienced severe arm swelling. One in every 250 adults who receive the Tdap vaccine develops a 102 degrees Fahrenheit or higher fever.

During Tdap clinical trials, two adults experienced temporary nervous system problems. It's unclear whether the vaccine caused this. Tdap or Td vaccination has resulted in severe arm swelling where the shot was administered in rare cases.

COVID-19 Impact Analysis

According to preliminary data, people who have received vaccines have a lower risk of developing severe diseases. Scientists believe vaccines accomplish this by priming the innate immune response to fight. Recent research has looked into inactivated vaccines, particularly diphtheria, tetanus, and pertussis (DTP) vaccines, to see if previous immunizations result in less severe COVID-19 manifestations. A study published in 2020 looked into the bacterial vaccines DTP and concluded that children's possible protection against SARS-CoV-2 could be attributed to cross-reactivity induced by these vaccinations.

Segment Analysis

By product type, the DTaP vaccine segment is expected to dominate the market growth

Diphtheria, tetanus, and pertussis can be prevented with the DTaP vaccine. Diphtheria and pertussis are contagious diseases that spread from person to person. Tetanus enters the body through open wounds or cuts. Diphtheria is a respiratory disease resulting in difficulty breathing, paralysis, heart failure, and death. It's extremely contagious and spreads through coughing and sneezing. Tetanus, also known as lockjaw, is caused by bacteria commonly found in soil. When it enters the body, it releases a toxin that attacks the nervous system, resulting in muscle spasms and death if not treated. Pertussis, also highly contagious, causes severe coughing spasms that make it difficult for infants to eat, drink, or even breathe. It can cause pneumonia, seizures, brain damage, and death.

Children under the age of seven are eligible for DTaP. Tetanus, diphtheria, and pertussis (Tdap and Td) vaccines are available for older children, adolescents, and adults. Children should receive five doses of DTaP at the ages of two months, four months, six months, 15 to 18 months, and four to six years. DTaP can be administered as a separate vaccine or as part of a combination vaccine (a type of vaccine that combines more than one vaccine into one-shot). DTaP can be given alongside other vaccines. Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, Quadracel, and Vaxelis are the seven paediatric DTaP vaccines currently licensed and used in the United States.

Geographical Analysis

North America region is expected to hold the largest market share in the global pertussis vaccine market

The increasing incidence of whooping cough is expected to drive the market growth in the forecast period.

The Centers for Disease Control and Prevention (CDC) reported 48,277 cases of pertussis in the United States. As of 2020, the number of pertussis cases in the United States of America was 18,617, accounting for 29.05 percent of all pertussis cases worldwide. Hence, with the increasing incidence of whooping cough, the demand for pertussis vaccine is expected to drive the market growth in this region.

In the United States, there are two vaccines available to help prevent pertussis. The DTaP is for children under seven, and the Tdap is for older children, teens, and adults. These vaccines are highly recommended, and most children and adolescents get them. In 2017, approximately 83% of children aged 19 to 35 months received the DTaP vaccine.

Competitive Landscape

The global pertussis vaccine market is moderately competitive with mergers, collaborations, and product launches. Some of the key players in the market are Sanofi, GlaxoSmithKline, Novartis AG, Seqirus, Merck Sharp & Dohme Corp., and Astellas Pharma US, Inc., KM Biologics

GlaxoSmithKline

Overview: GlaxoSmithKline is a science-led global healthcare company. It is the world's largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life. The company was founded in 2000. It has headquarters in the United Kingdom.

Product Portfolio: The company's BOOSTRIX is a vaccine for active booster immunization against tetanus, diphtheria, and pertussis in people aged 10 and up. It is available as single-dose vials and prefilled syringes with a 0.5-mL injection suspension.

Key Development: On 23rd June 2021, The new GSK prioritized R&D and commercial investment in Vaccines and Specialty Medicines, which are expected to account for roughly three-quarters of company sales by 2026.

Why Purchase the Report?

Visualize the composition of the global pertussis vaccine market segmentation by product type, by vaccine type, and end user highlighting the key commercial assets and players.

Identify commercial opportunities in global pertussis vaccine market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global pertussis vaccine market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global pertussis vaccine market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Pertussis Vaccine Market- By Product Type

DTaP vaccine

Daptacel

Infanrix

Kinrix

Pediarix

Pentacel

Quaracel

Tdap vaccine

Boostrix

Adacel

Global Pertussis Vaccine Market- By Vaccine Type

Whole-cell vaccine

Acellular vaccine

Global Pertussis Vaccine Market- By End User

Hospitals

Clinics

Vaccination Centers

Other

Global Pertussis Vaccine Market- By Region

North America

Europe

South America

Asia Pacific

Middle East and Africa

Table of Contents

1. Global Pertussis Vaccine MarketMethodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Pertussis Vaccine Market- Market Definition and Overview

3. Global Pertussis Vaccine Market- Executive Summary

  • 3.1. Market Snippet By Product Type
  • 3.2. Market Snippet By Vaccine Type
  • 3.3. Market Snippet By End User
  • 3.4. Market Snippet By Region

4. Global Pertussis Vaccine Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The adoption of pertussis vaccination
    • 4.1.2. Restraints:
      • 4.1.2.1. The side effects associated with pertussis vaccine
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Pertussis Vaccine Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs

6. Global Pertussis Vaccine Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Pertussis Vaccine Market- By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 7.3. Market Attractiveness Index, By Product Type
    • 7.3.1. DTaP vaccine*
      • 7.3.1.1.1. Introduction
      • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
      • 7.3.1.1.3. Daptacel
      • 7.3.1.1.4. Infanrix
      • 7.3.1.1.5. Kinrix
      • 7.3.1.1.6. Pediarix
      • 7.3.1.1.7. Pentacel
      • 7.3.1.1.8. Quaracel
    • 7.3.2. Tdap vaccine
      • 7.3.2.1. Boostrix
      • 7.3.2.2. Adacel

8. Global Pertussis Vaccine Market- By Vaccine Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 8.3. Market Attractiveness Index, By Vaccine Type
    • 8.3.1. Whole-cell vaccine
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    • 8.3.2. Acellular vaccine

9. Global Pertussis Vaccine Market- By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Clinics
  • 9.4. Vaccination Centers
  • 9.5. Other

10. Global Pertussis Vaccine Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.5.1. U.S.
      • 10.2.5.2. Canada
      • 10.2.5.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.5.1. Brazil
      • 10.4.5.2. Argentina
      • 10.4.5.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.5.1. China
      • 10.5.5.2. India
      • 10.5.5.3. Japan
      • 10.5.5.4. Australia
      • 10.5.5.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Pertussis Vaccine Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Pertussis Vaccine Market- Company Profiles

  • 12.1. GlaxoSmithKline*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanofi
  • 12.3. Novartis AG
  • 12.4. Seqirus
  • 12.5. Merck Sharp & Dohme Corp
  • 12.6. Astellas Pharma US, Inc.
  • 12.7. KM Biologics

LIST NOT EXHAUSTIVE

13. Global Pertussis Vaccine Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us